Development of a broadly protective modified-live virus vaccine candidate against porcine reproductive and respiratory syndrome virus

Haiyan Sun, Aspen Workman, Fernando A. Osorio, David J Steffen, Hiep L Vu

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Modified-live virus (MLV) vaccines are widely used to protect pigs against porcine reproductive and respiratory syndrome virus (PRRSV). However, current MLV vaccines do not confer adequate levels of heterologous protection, presumably due to the substantial genetic diversity of PRRSV isolates circulating in the field. To overcome this genetic variation challenge, we recently generated a synthetic PRRSV strain containing a consensus genomic sequence of PRRSV-2. We demonstrated that our synthetic PRRSV strain confers unprecedented levels of heterologous protection. However, the synthetic PRRSV strain at passage 1 (hereafter designated CON-P1) is highly virulent and therefore, is not suitable to be used as a vaccine in pigs. In the present study, we attenuated CON-P1 by continuously passaging the virus in MARC-145 cells, a non-natural host cell line. Using a young pig model, we demonstrated that the synthetic virus at passages 90 and 122 (designated as CON-P90 and CON-P122, respectively) were fully attenuated, as evidenced by the significantly reduced viral loads in serum and tissues and the absence of lung lesion in the infected pigs. Most importantly, CON-P90 confers similar levels of heterologous protection as its parental strain CON-P1. Taken together, the results indicate that CON-P90 is an excellent candidate for the formulation of next generation of PRRSV MLV vaccines with improved levels of heterologous protection.

Original languageEnglish (US)
Pages (from-to)66-73
Number of pages8
JournalVaccine
Volume36
Issue number1
DOIs
StatePublished - Jan 2 2018

Fingerprint

Porcine respiratory and reproductive syndrome virus
Porcine reproductive and respiratory syndrome virus
Vaccines
vaccines
Viruses
viruses
Swine
swine
genetic variation
Consensus Sequence
viral load
Viral Load
lesions (animal)
lungs
cell lines
genomics
Cell Line
Lung
Serum

Keywords

  • Heterologous protection
  • MLV
  • PRRSV
  • Synthetic virus

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Development of a broadly protective modified-live virus vaccine candidate against porcine reproductive and respiratory syndrome virus. / Sun, Haiyan; Workman, Aspen; Osorio, Fernando A.; Steffen, David J; Vu, Hiep L.

In: Vaccine, Vol. 36, No. 1, 02.01.2018, p. 66-73.

Research output: Contribution to journalArticle

@article{6db24c2a730846db954084f8b3e5684e,
title = "Development of a broadly protective modified-live virus vaccine candidate against porcine reproductive and respiratory syndrome virus",
abstract = "Modified-live virus (MLV) vaccines are widely used to protect pigs against porcine reproductive and respiratory syndrome virus (PRRSV). However, current MLV vaccines do not confer adequate levels of heterologous protection, presumably due to the substantial genetic diversity of PRRSV isolates circulating in the field. To overcome this genetic variation challenge, we recently generated a synthetic PRRSV strain containing a consensus genomic sequence of PRRSV-2. We demonstrated that our synthetic PRRSV strain confers unprecedented levels of heterologous protection. However, the synthetic PRRSV strain at passage 1 (hereafter designated CON-P1) is highly virulent and therefore, is not suitable to be used as a vaccine in pigs. In the present study, we attenuated CON-P1 by continuously passaging the virus in MARC-145 cells, a non-natural host cell line. Using a young pig model, we demonstrated that the synthetic virus at passages 90 and 122 (designated as CON-P90 and CON-P122, respectively) were fully attenuated, as evidenced by the significantly reduced viral loads in serum and tissues and the absence of lung lesion in the infected pigs. Most importantly, CON-P90 confers similar levels of heterologous protection as its parental strain CON-P1. Taken together, the results indicate that CON-P90 is an excellent candidate for the formulation of next generation of PRRSV MLV vaccines with improved levels of heterologous protection.",
keywords = "Heterologous protection, MLV, PRRSV, Synthetic virus",
author = "Haiyan Sun and Aspen Workman and Osorio, {Fernando A.} and Steffen, {David J} and Vu, {Hiep L}",
year = "2018",
month = "1",
day = "2",
doi = "10.1016/j.vaccine.2017.11.028",
language = "English (US)",
volume = "36",
pages = "66--73",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Development of a broadly protective modified-live virus vaccine candidate against porcine reproductive and respiratory syndrome virus

AU - Sun, Haiyan

AU - Workman, Aspen

AU - Osorio, Fernando A.

AU - Steffen, David J

AU - Vu, Hiep L

PY - 2018/1/2

Y1 - 2018/1/2

N2 - Modified-live virus (MLV) vaccines are widely used to protect pigs against porcine reproductive and respiratory syndrome virus (PRRSV). However, current MLV vaccines do not confer adequate levels of heterologous protection, presumably due to the substantial genetic diversity of PRRSV isolates circulating in the field. To overcome this genetic variation challenge, we recently generated a synthetic PRRSV strain containing a consensus genomic sequence of PRRSV-2. We demonstrated that our synthetic PRRSV strain confers unprecedented levels of heterologous protection. However, the synthetic PRRSV strain at passage 1 (hereafter designated CON-P1) is highly virulent and therefore, is not suitable to be used as a vaccine in pigs. In the present study, we attenuated CON-P1 by continuously passaging the virus in MARC-145 cells, a non-natural host cell line. Using a young pig model, we demonstrated that the synthetic virus at passages 90 and 122 (designated as CON-P90 and CON-P122, respectively) were fully attenuated, as evidenced by the significantly reduced viral loads in serum and tissues and the absence of lung lesion in the infected pigs. Most importantly, CON-P90 confers similar levels of heterologous protection as its parental strain CON-P1. Taken together, the results indicate that CON-P90 is an excellent candidate for the formulation of next generation of PRRSV MLV vaccines with improved levels of heterologous protection.

AB - Modified-live virus (MLV) vaccines are widely used to protect pigs against porcine reproductive and respiratory syndrome virus (PRRSV). However, current MLV vaccines do not confer adequate levels of heterologous protection, presumably due to the substantial genetic diversity of PRRSV isolates circulating in the field. To overcome this genetic variation challenge, we recently generated a synthetic PRRSV strain containing a consensus genomic sequence of PRRSV-2. We demonstrated that our synthetic PRRSV strain confers unprecedented levels of heterologous protection. However, the synthetic PRRSV strain at passage 1 (hereafter designated CON-P1) is highly virulent and therefore, is not suitable to be used as a vaccine in pigs. In the present study, we attenuated CON-P1 by continuously passaging the virus in MARC-145 cells, a non-natural host cell line. Using a young pig model, we demonstrated that the synthetic virus at passages 90 and 122 (designated as CON-P90 and CON-P122, respectively) were fully attenuated, as evidenced by the significantly reduced viral loads in serum and tissues and the absence of lung lesion in the infected pigs. Most importantly, CON-P90 confers similar levels of heterologous protection as its parental strain CON-P1. Taken together, the results indicate that CON-P90 is an excellent candidate for the formulation of next generation of PRRSV MLV vaccines with improved levels of heterologous protection.

KW - Heterologous protection

KW - MLV

KW - PRRSV

KW - Synthetic virus

UR - http://www.scopus.com/inward/record.url?scp=85035066209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035066209&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2017.11.028

DO - 10.1016/j.vaccine.2017.11.028

M3 - Article

C2 - 29174314

AN - SCOPUS:85035066209

VL - 36

SP - 66

EP - 73

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 1

ER -